Tenpoint Therapeutics is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, ...

US digital physical therapy specialist Sword Health has bought its competitor Kaia Health for $285 million, positioning it ...

On behalf of Lilly, Seamless will design and programme recombinases that can correct alterations in multiple genes involved ...

The Surf Bio acquisition comes shortly after Halozyme bought another company with a subcutaneous delivery technology, Elektrofi, for $750 million in cash and possible milestones of $150 million.

Traditional cell therapies rely on “clean targets” – antigens that are found on cancer cells but not on healthy cells. Where ...

By prioritising gentler, patient-focused approaches, the field of paediatric MRI has seen significant advances, while its use ...

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder (ADHD), centanafadine, setting up a decision by 24th July.

That is the conclusion of the annual assessment of the sector's ability to attract financing by the BioIndustry Association ...

The South San Francisco startup is offering 17.6 million shares at a price range of $16 to $18, which would give the company a valuation at the top end of more than $900 million. The IPO follows ...

In its new incarnation, apecotrep has been shown to reduce protein in the urine (proteinuria) – a biomarker for kidney ...

The list has been announced by the Centers for Medicare & Medicaid Services (CMS) shortly after the reductions agreed for the ...

Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) ...